PRODUCT PATENTS

In accordance with 35 U.S.C. § 287(a), the following list used in conjunction with the labeling approved by the U.S. Food and Drug Administration may be used to determine patents associated with the corresponding U.S. marketed product. Additional patents may be pending in the U.S. and in other countries. The following list may not be all inclusive, and other products not listed here may be protected by one or more patents in the U.S. and additional countries.

Patents associated with SKYTROFA^® (lonapegsomatropin-tcgd) lyophilized powder for solution, for subcutaneous use:

7,879,588
8,377,917
8,450,097
9,238,686
9,272,048
9,511,122
9,919,033
10,098,930
10,682,395
10,799,563
10,835,677
10,960,053
11,179,524
11,351,305
11,406,760
11,517,673
11,524,115
11,607,496
11,684,724
11,738,147
11,957,880
11,969,581
12,005,241
12,016,903
12,133,883
D907,765

Patents associated with YORVIPATH® (palopegteriparatide) injection, for subcutaneous use: